Product | Rights Authorized Region*** | Indication | Clinical Trial Approval | Clinical Trial for Registration | Marketing Application | Marketed | Major Marketed Regions | |||
---|---|---|---|---|---|---|---|---|---|---|
CN | US | EU | JP | |||||||
Methotrexate Injection | ![]() |
Severe recalcitrant disabling psoriasis and other autoimmune diseases | √ | √ | ||||||
Adult rheumatoid arthritis | √ | |||||||||
Diazepam Nasal Spray | ![]() |
Intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) in patients with epilepsy six years of age and older | √ | |||||||
Tildrakizumab Solution for Injection (Biological Agent) |
![]() |
Moderate-to-severe plaque psoriasis | √ (HK) |
√ (US) |
√ (OU) |
√ (JAP) |
||||
Methylthioninium Chloride Enteric-coated Sustained-release Tablets | ![]() |
An diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy | √ | |||||||
Desidustat Tablets | ![]() |
Anemia in patients with chronic kidney disease | ||||||||
Cyclosporine Eye Drops 0.09% | ![]() |
Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye) | √ | |||||||
PLENITY | ![]() ![]() |
An aid for weight management in adults with a BMI of 25-40 kg/m2 when used in conjunction with diet and exercise | √ | √ | ||||||
Latanoprost Eye Drops | ![]() |
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension | √ | |||||||
Levetiracetam XR Tablet | ![]() |
Adjunctive therapy for the treatment of partial-onset seizures | √ | |||||||
BCG for Intravesical Instillation (Biological Agent) |
![]() |
Non-invasive urothelial bladder carcinoma, including curative treatment of carcinoma in situ and prophylactic treatment of recurrence | √ | |||||||
PoNS | ![]() |
Chronic balance deficit due to mild-to-moderate traumatic brain injury |
**Taiwan is not included in the rights authorized region of BCG for Intravesical Instillation
*** CMS has NO development, commercialization and other related products’ rights in any unauthorized region
Product | Rights Authorized Region*** | Indication | Pre-clinical | Clinical Trial Approval | Phase I | Phase II | Phase III | Marketing Application |
---|---|---|---|---|---|---|---|---|
SDN – 037 | ![]() |
Eye pain and inflammation after cataract surgery | ||||||
PDP – 716 | ![]() |
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension | ||||||
CF101 | ![]() |
Psoriasis | ||||||
ACT017 (Biological Agent) |
![]() ![]() |
Acute phase of ischemic stroke | ||||||
CF102 | ![]() |
Hepatocellular carcinoma | ||||||
Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis | ||||||||
XF – 73 | ![]() ![]() |
Prevention of post-surgical staphylococcal infections | ||||||
Infectious diseases | ||||||||
BB2603 | ![]() ![]() |
Onychomycosis and tinea pedis | ||||||
VXM01 (Biological Agent) |
![]() ![]() |
Recurrent glioblastoma | ||||||
VEGF/ANG2 Tetravalent Bispecific Antibody (Biological Agent) |
![]() |
Intended to be used for ocular fundus neovascular diseases | ||||||
Fully Human Anti-SA Hlα Antibody (Biological Agent) |
![]() |
Intended to be used to prevent disease progression in high-risk groups for SA colonization and treat pneumonia, bacteremia, and toxic shock caused by SA, especially MRSA | ||||||
Fully Human Anti-HCMV Antibody (Biological Agent) |
![]() |
Intended to be used for prophylaxis of HCMV infection | ||||||
Fully Human Anti-COVID-19 Antibody (Biological Agent) |
![]() |
Intended to be used for prevention and treatment of COVID-19 infection | ||||||
Fully Human Anti-rabies Virus Antibody (Biological Agent) |
![]() |
Intended to be used for rapid passive immunization of patients bitten and scratched by rabies infected dogs or other animals susceptible to rabies infection | ||||||
CMS — D001 | ![]() |
Autoimmune diseases | ||||||
CMS — D002 | ![]() |
Gynecological diseases | ||||||
CMS — D003 | ![]() |
Cardio-cerebrovascular diseases | ||||||
CMS — D004 | ![]() |
Central nervous system diseases | ||||||
CMS — D005 | ![]() |
Metabolic diseases |
*** CMS has NO development, commercialization and other related products’ rights in any unauthorized region